ExodusPoint Capital Management LP Makes New $759,000 Investment in Sage Therapeutics, Inc. (NASDAQ:SAGE)

ExodusPoint Capital Management LP bought a new position in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 139,748 shares of the biopharmaceutical company's stock, valued at approximately $759,000. ExodusPoint Capital Management LP owned approximately 0.23% of Sage Therapeutics at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of SAGE. Charles Schwab Investment Management Inc. grew its stake in shares of Sage Therapeutics by 10.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 452,193 shares of the biopharmaceutical company's stock worth $3,265,000 after acquiring an additional 43,617 shares in the last quarter. BNP Paribas Financial Markets grew its stake in Sage Therapeutics by 52.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 70,986 shares of the biopharmaceutical company's stock worth $513,000 after purchasing an additional 24,356 shares in the last quarter. State Street Corp grew its stake in Sage Therapeutics by 18.2% during the 3rd quarter. State Street Corp now owns 2,926,239 shares of the biopharmaceutical company's stock worth $21,127,000 after purchasing an additional 451,377 shares in the last quarter. Geode Capital Management LLC increased its holdings in Sage Therapeutics by 0.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,242,854 shares of the biopharmaceutical company's stock worth $8,975,000 after purchasing an additional 3,757 shares during the period. Finally, SG Americas Securities LLC raised its position in Sage Therapeutics by 57.7% in the 4th quarter. SG Americas Securities LLC now owns 22,498 shares of the biopharmaceutical company's stock valued at $122,000 after purchasing an additional 8,228 shares in the last quarter. 99.22% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Scotiabank cut their target price on shares of Sage Therapeutics from $14.00 to $12.00 and set a "sector outperform" rating on the stock in a research note on Wednesday, February 12th. Stifel Nicolaus dropped their price objective on shares of Sage Therapeutics from $10.00 to $6.00 and set a "hold" rating on the stock in a research report on Monday, December 16th. HC Wainwright reaffirmed a "neutral" rating and set a $12.00 price objective (down from $14.00) on shares of Sage Therapeutics in a research report on Wednesday, February 12th. Needham & Company LLC reissued a "hold" rating on shares of Sage Therapeutics in a report on Wednesday, February 12th. Finally, Wedbush reaffirmed a "neutral" rating and set a $6.00 price target on shares of Sage Therapeutics in a report on Wednesday, February 12th. Three equities research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, Sage Therapeutics presently has an average rating of "Hold" and an average price target of $8.81.

Sage Therapeutics Stock Performance

Sage Therapeutics stock traded up $0.14 during midday trading on Tuesday, hitting $7.54. 845,732 shares of the company's stock were exchanged, compared to its average volume of 1,250,199. The stock has a market cap of $463.57 million, a price-to-earnings ratio of -1.14 and a beta of 0.48. Sage Therapeutics, Inc. has a 12-month low of $4.62 and a 12-month high of $15.74. The firm's 50 day simple moving average is $7.45 and its 200 day simple moving average is $6.71.

Sage Therapeutics (NASDAQ:SAGE - Get Free Report) last released its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported ($1.56) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.54) by ($0.02). Sage Therapeutics had a negative return on equity of 68.18% and a negative net margin of 971.50%. On average, equities research analysts forecast that Sage Therapeutics, Inc. will post -3.52 EPS for the current fiscal year.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.